News articles about Amedisys Home Health and Hospice Care (NASDAQ:AMED) have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amedisys Home Health and Hospice Care earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the health services provider an impact score of 45.6893682183105 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of equities research analysts have weighed in on the stock. BidaskClub raised shares of Amedisys Home Health and Hospice Care from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research raised shares of Amedisys Home Health and Hospice Care from a “hold” rating to a “buy” rating and set a $57.00 price target for the company in a report on Tuesday, February 6th. TheStreet downgraded shares of Amedisys Home Health and Hospice Care from a “b” rating to a “c+” rating in a report on Wednesday, February 28th. Oppenheimer upped their price target on shares of Amedisys Home Health and Hospice Care from $68.00 to $63.00 and gave the company an “outperform” rating in a report on Thursday, March 1st. Finally, Robert W. Baird set a $66.00 price target on shares of Amedisys Home Health and Hospice Care and gave the company a “hold” rating in a report on Thursday, March 1st. Five equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Amedisys Home Health and Hospice Care presently has a consensus rating of “Buy” and a consensus target price of $63.18.
AMED stock opened at $65.08 on Friday. The company has a quick ratio of 1.45, a current ratio of 1.45 and a debt-to-equity ratio of 0.15. Amedisys Home Health and Hospice Care has a one year low of $45.60 and a one year high of $66.25. The stock has a market cap of $2,241.64, a price-to-earnings ratio of 29.45, a PEG ratio of 1.26 and a beta of 0.65.
TRADEMARK VIOLATION WARNING: This news story was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://dakotafinancialnews.com/2018/04/14/amedisys-home-health-and-hospice-care-amed-given-daily-media-impact-score-of-0-17.html.
About Amedisys Home Health and Hospice Care
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Receive News & Ratings for Amedisys Home Health and Hospice Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Home Health and Hospice Care and related companies with MarketBeat.com's FREE daily email newsletter.